Pharma e Biotech - USA MRNA (biotech nasdaq)

peggio di questo titolo conosco solo DARA

DARA fece un -99% senza rimbalzi
con la sfig.a che ho succede lo stesso

in 10 mesi hanno diluito quasi del 90% la quotazione
dal top dello spike a 14 $ a 0,72 minimo di ieri ha perso il 95% in nemmeno 2 anni
 
ante revers split a 0,72 è come se fosse a 0,16 circa.
con la capitalizzazione che ha non è giustificata la quotazione.

quindi...
o kaput
o attacco short che in chiusura porterebbe a spike mostruoso.

sarà kaput...
 
con il cross media a 0,8150
ieri close a 0,70

un disastro.

tengo duro fino a 0,67 che è il min storico post reverse.
 
0,8250 grazie al cross
e il titolo in rosso anche oggi.

0,68...
ormai rimane il min storico a 0,67...

sotto esco on forte loss
 
8:53AM Freeport-McMoRan announces redemption of its 8.25% senior notes due 2015 (FCX) 51.01 : Co announces that it has issued a notice to redeem all of its outstanding 8.25% Senior Notes due 2015 on April 1, 2011. ~$1.1 billion aggregate principal amount of Notes is currently outstanding. Holders of record will receive 104.125 percent of the principal amount together with accrued and unpaid interest from October 1, 2010 to the redemption date. The Notes bear interest at 8.25% per annum. The annual interest cost savings would average ~$90 million per annum. FCX expects to record an ~$49 million charge to net income in the second quarter of 2011 in connection with the redemption. The Bank of New York Mellon Trust Company, N.A., as trustee, has distributed to the registered note holder written notice of the terms of the redemption.

8:47AM On The Wires (WIRES) :
  • Naviscan announced that it has entered into an exclusive licensing agreement with Neoprobe (NEOP) as a partner to further develop its patented imaging technology.
  • Nevada Gold & Casinos (UWN) announced it has met with the Nevada Gaming Control Board and is in the process of applying for a gaming license in the state of Nevada.
  • ATP Oil & Gas Corporation (ATPG) is expanding its deepwater operating and infrastructure expertise to offshore Israel. Subject to approval of the Ministry of National Infrastructures, ATP has signed agreements to acquire five licenses, of which two are pending, in approximately 4,000 feet of water.
  • Capstone Turbine Corporation (CPST) received an order for 24 additional C65 microturbines for one of the world's largest independent oil and natural gas companies. This order is a follow-on order to an 18-unit C65 order received in August 2010. All 18 of the C65s purchased in August 2010 have been successfully commissioned by Capstone distributor Pumps & Service.
  • ZST Digital Networks (ZSTN) announced that it has entered into an agreement with the Road Transportation Department of Shangqiu City to develop a city-wide GPS tracking platform for commercial vehicles.
  • BioSante Pharmaceuticals (BPAX) announced that enrollment of subjects in the first of two pivotal Phase III LibiGel (testosterone gel) safety and efficacy trials has been completed. The efficacy trials are being conducted under an FDA-approved special protocol assessment agreement.
8:38AM News Corp announces purchase of $227,424,000 principal amount of certain of its debt securities (NWS) 17.70 : Co announces that its previously announced cash tender offer for any and all of its outstanding 9 1/4 % Senior Debentures due February 1, 2013 expired at 5:00 p.m., New York City time, on February 23, 2011. Co accepted for purchase all of the Securities which were validly tendered and not validly withdrawn prior to the expiration of the Offer, representing a total aggregate principal amount of $227,424,000.
8:37AM GTX reports EPS in-line, misses on revs (GTXI) 2.64 : Reports Q4 (Dec) loss of $0.16 per share, in-line with the Thomson Reuters consensus of ($0.16); revenues fell 51.4% year/year to $1.8 mln vs the $2.9 mln consensus.
8:37AM Avon Products announces that an external search is underway for a new CFO; co said that Cramb will continue to serve as co's CFO on an interim basis pending the announcement of the new CFO (AVP) 27.94 :
8:35AM IntercontinentalExchange announces that ICE Futures Europe set an exchange-wide daily volume record of 1,626,277 contracts on February 23rd (ICE) 122.73 :
8:34AM Smart Balance misses by $0.01, beats on revs; reaffirms FY11 outlook (SMBL) 4.18 : Reports Q4 (Dec) earnings of $0.01 per share, $0.01 worse than the Thomson Reuters consensus of $0.02; revenues rose 6.6% year/year to $62.8 mln vs the $60 mln consensus, reflecting the growth of the co's sales of enhanced milks and spreads products partially offset by declines in sales for grocery products and higher promotional expenses. The Company's enhanced milks sales growth resulted from the national expansion of distribution in 2010 as well as continued growth in the established markets of Florida and the Northeast. Co reaffirms FY11 outlook: The co expects net sales in 2011 to grow in the mid-single digit percentage range YoY vs. +5.8% consensus. The co expects growth to be driven by pricing, primarily in the core category of spreads, and volume growth in milk, partially offset by higher promotional spending. The co indicated that it is too soon to determine consumer reaction to the spreads category pricing. The co expects cash operating income in 2011 to grow in the high single-digit percentage range.
8:33AM KMG Chemicals approves a 25% increase to the co's cash dividend to an annual rate of $0.10 per common share (KMGB) :
8:33AM Teekay Shipping misses by $0.10 (TK) 35.19 : Reports Q4 (Dec) loss of $0.51 per share, $0.10 worse than the Thomson Reuters consensus of ($0.41).
8:33AM Christopher & Banks appoints Michael Lyftogt as Senior Vice President, CFO (CBK) 6.12 : Co announced that Michael Lyftogt has been elected Senior Vice President, CFO of the Company. Mr. Lyftogt has worked at the Company for twelve years in a variety of financial roles including Chief Accounting Officer and Vice President, Finance and has served as Interim Chief Financial Officer since July 2010.
8:31AM Marina Biotech reports interim results of their Phase 2-enabling toxicology study for CEQ508; no test article-related adverse responses were identified; no evidence of local immune activation (MRNA) 0.70 : Co announces it has completed a 9 month toxicology study in non-human primates with its first drug candidate, CEQ508. CEQ508 is currently in a Phase 1b/2a clinical development program and is intended for the treatment of Familial Adenomatous Polyposis. The results show no test article-related adverse responses were identified in the following parameters: clinical observations, body weights and temperatures, serum chemistry, coagulation, hematology, urinalysis, cytokines and gross pathology. Additionally, monthly biopsies of colonic mucosa showed no evidence of local immune activation. CEQ508 was recently granted Orphan Drug Designation by the FDA's Office of Orphan Products Development.

8:19AM On The Wires (WIRES) :
  • China Advanced Construction Materials Group (CADC) announced it has been awarded two high-speed rail contracts valued at $4.1 million total.
  • Masimo (MASI) and Royal Fornia Electronic Device jointly announce a worldwide technology licensing agreement to integrate Masimo rainbow SET Pulse CO-Oximetry technology into Royal Fornia's new generation of multiparameter patient monitors.
  • Tsakos Energy Navigation Limited (TNP) announced two-year time charter extensions for two of its 2009 Korean-built panamax tankers, Chantal and World Harmony. These fixtures will continue with the same charterer, a major South American state affiliated oil entity, at a minimum base rate with open upside for the Company. The gross revenues from the extension of these two charters, assuming only the minimum rate, are expected to be ~$22 million over the corresponding period.
  • iGo (IGOI) announced the signing of a marketing, distribution and licensing agreement with PureEnergy Solutions, the world's only manufacturer of rechargeable alkaline batteries.
  • Equinix (EQIX) announced that they will jointly sell and market to federal agencies, financial and healthcare enterprises with high security and data protection needs.
  • JA Solar (JASO) announces $4.5 mln class action lawsuit settlement.
  • Amyris (AMRS) announced that it has entered into an agreement with Givaudan. Under the agreement, Givaudan will develop a derivative of Biofene to be used as a building block for one of the most important proprietary fragrance ingredients in Givaudan's palette. Biofene is the chemical, farnesene, produced using Amyris's bio-based technology and production platform.
  • Acuity Brands (AYI) announced it has acquired for cash Sacramento, CA-based Sunoptics, a premier provider of high-performance, prismatic daylighting products.
  • DemandTec (DMAN) announced the opening of a new office in Minneapolis, Minn. at 50 South 10th Street, Suite 510.
  • Iconic American brand, Keds, a Collective Brands (PSS) business, announced an exclusive licensing agreement with LF USA, a subsidiary of Hong Kong-headquartered multinational Li & Fung Limited, to develop a line of Keds branded apparel for women and men to be sold in retail stores across the U.S. and its territories beginning next year.
  • Youku.com (YOKU) recently received several new licenses allowing it to expand its video services in live broadcasting, video search, and production and distribution of original content.
8:18AM El Paso Pipeline Partners misses by $0.02, beats on revs (EPB) 37.05 : Reports Q4 (Dec) earnings of $0.50 per share, $0.02 worse than the Thomson Reuters consensus of $0.52; revenues rose 13.9% year/year to $352.1 mln vs the $292.6 mln consensus.
8:16AM Vulcan Materials announces that it has received favorable results in two recent arbitrations (VMC) 43.41 : In the first arbitration, which related to the settlement in 2007 of two lawsuits brought against the Company's divested Chemicals business, the Company was awarded $13.5 million against one of its insurers. Of this award, $6 million pretax was recognized in earnings in the third quarter of 2010. The remaining $7.5 million pretax amount will be recognized in earnings in the first quarter of 2011. When combined with settlements reached earlier with four other insurers, the Company now has recovered $37.9 million of the total amounts paid in settlement and for defense expenses in this litigation. The second arbitration related to the $40 million settlement announced on May 18, 2010 of a lawsuit brought against the Company by the State of Illinois and the Illinois Department of Transportation. The Company recorded a charge against earnings for this amount and certain related defense expenses in the second quarter of 2010. In this arbitration, the panel ordered that the Company was entitled to recover $25.5 million under two insurance policies for a portion of the amounts paid in settlement and for defense expenses. The $25.5 million pretax award will be recognized in earnings in the first quarter of 2011.
8:09AM US Cellular misses by $0.14, reports revs in-line (USM) 46.87 : Reports Q4 (Dec) earnings of $0.08 per share, $0.14 worse than the Thomson Reuters consensus of $0.22; revenues rose 0.3% year/year to $1.06 bln vs the $1.07 bln consensus. For FY11, projects service revs of $4.0-$4.1 bln, adjusted OIBDA of $775-$875 mln, operating income of $185-$285 mln, and capex of ~$650 mln.
8:06AM FelCor Lodging beats by $0.04, reports revs in-line; guides FY11 FFO in-line (FCH) 7.24 : Reports Q4 (Dec) loss of $0.04 per share, $0.04 better than the Thomson Reuters consensus of ($0.08); revenues rose 10.4% year/year to $232.2 mln vs the $232.3 mln consensus. Same-store RevPAR for 80 consolidated hotels was $79.77, a 5.7% increase compared to the same period in 2009. This increase was driven by a 4.2% occupancy increase to 66.2% and a 1.5% average daily rate increase to $120.47. Co issues in-line guidance for FY11, sees funds from operations of $0.21-0.32 vs. $0.24 Thomson Reuters consensus. For FY11 co sees same-store RevPAR for 81 hotels (including the Fairmont Copley Plaza's results for both years) to increase between 6% and 8%.
8:06AM Valeant Pharmaceuticals beats by $0.06, reports revs in-line; guides FY11 EPS in-line, above prior guidance; agrees to repurchase $275 mln in common shares from institution (VRX) 38.71 : Reports Q4 (Dec) earnings of $0.51 per share, $0.06 better than the Thomson Reuters consensus of $0.45; revenues rose 113.4% year/year to $514.6 mln vs the $514.2 mln consensus. Co issues in-line guidance for FY11, sees EPS of $2.45-2.70 vs. $2.51 Thomson Reuters consensus and up from prior guidance of $2.25-2.50. Additionally, co agrees to repurchase common shares from ValueAct Capital for $275 mln at a 5.77% discount over a 20-day trading day average.
8:04AM Pinnacle beats by $0.07, reports revs in-line (PNK) 13.49 : Reports Q4 (Dec) loss of $0.01 per share, $0.07 better than the Thomson Reuters consensus of ($0.08); revenues rose 18.6% year/year to $274 mln vs the $274.8 mln consensus.
8:04AM SureWest Comm beats by $0.09, reports revs in-line (SURW) 12.31 : Reports Q4 (Dec) earnings of $0.14 per share, $0.09 better than the Thomson Reuters consensus of $0.05; revenues rose 0.8% year/year to $61.6 mln vs the $61.3 mln consensus.
8:03AM Brush Engineered Materials beats by $0.15, beats on revs; guides FY11 EPS in-line, revs above consensus (BW) 34.46 : Reports Q4 (Dec) earnings of $0.61 per share, $0.15 better than the Thomson Reuters consensus of $0.46; revenues rose 65.4% year/year to $356 mln vs the $305.1 mln consensus. Co issues guidance for FY11, sees EPS of $2.20-2.50 vs. $2.32 Thomson Reuters consensus; sees FY11 revs of $1.45-1.50 bln vs. $1.33 bln Thomson Reuters consensus, ~5 points of the anticipated 5-11% growth is due to higher metal prices.
8:02AM Capella Education authorizes an increase of the existing share repurchase program by $65 mln up to an aggregate of $113 mln (CPLA) 56.43 : This includes the $48 mln remaining authorization as of Dec. 31, 2010 under the previous share repurchase program.
8:02AM Inventure Foods reports EPS in-line, beats on revs (SNAK) 4.22 : Reports Q4 (Dec) earnings of $0.05 per share, excluding non-recurring items, in-line with the Thomson Reuters consensus of $0.05; revenues rose 20.4% year/year to $33.6 mln vs the $31.4 mln consensus.
8:01AM School Specialty announces exchange transaction to retire 3.75% convertible subordinated debentures due 2026 (SCHS) 15.08 : Co enters into separate, privately-negotiated exchange agreements under which it will retire $100 million in aggregate principal of its outstanding 3.75% Convertible Subordinated Debentures due 2026. Following these transactions, $100 million in principal amount of the Existing Debentures will remain outstanding.
7:50AM Royal Bank of Scotland reports net loss of GBP 1.1 bln ($1.78 bln), below the expected GBP 406 mln consensus (RBS) 15.10 : RBS was impacted by Irish loan losses which amounted to approx GBP 1.1 bln. The bank did see some imporvements in bad-loan provision which fell to GBP 9.3 bln from GBP 13.9 bln. Operating profit at the investment bank was GBP 3.5 bln compared with GBP 5.7 bln in the prior year. And revenue continued to slow as it dipped to GBP 7.9 bln from GBP 11. 1 bln. The bank did see a large jump in operating profit at its consumer bank to GBP 1.37 bln from GBP 229 mln. RBS remains in the hands of the British government which owns 83% of the instituion after bailing it out during the credit crisis.
7:50AM Palatin Technologies announces pricing of public offering of common stock and warrants (PTN) 1.04 : Co announces the pricing of its underwritten public offering of 23 mln units, consisting of 23 mln shares of its common stock, Series A Warrants to purchase 2 mln shares of its common stock and Series B Warrants to purchase 21 mln shares of its common stock, at a price to the public of $1.00 per unit. Palatin expects that the net proceeds of the offering will be ~$21.1 mln after deducting underwriting discounts and commissions and other estimated offering expenses. Each unit consists of one share of common stock, a Series A Warrant exercisable for 0.087 of a share of common stock at an initial exercise price of $1.00 per share and a Series B Warrant exercisable for 0.913 of a share of common stock at an initial exercise price of $1.00 per share.
7:48AM iStar Financial reports adjusted EPS of ($0.42) vs ($0.55) Thomson Reuters consensus (SFI) 8.94 :
7:42AM CommonWealth REIT misses by $0.01 (CWH) 27.69 : Reports Q4 (Dec) funds from operations of $0.88 per share, $0.01 worse than the Thomson Reuters consensus of $0.89. As of December 31, 2010, 87.7% of CWH's total square feet was leased, compared to 86.4% as of September 30, 2010 and 88.8% as of December 31, 2009.
7:41AM Northstar Realty beats by $0.35, beats on revs (NRF) 5.13 : Reports Q4 (Dec) funds from operations of $0.48 per share, $0.35 better than the Thomson Reuters consensus of $0.13; revenues rose 122.3% year/year to $149.4 mln vs the $126 mln consensus.
7:41AM ViroPharma beats by $0.11, beats on revs (VPHM) 16.04 : Reports Q4 (Dec) earnings of $0.43 per share, $0.11 better than the Thomson Reuters consensus of $0.32; revenues rose 38.5% year/year to $121.6 mln vs the $114.5 mln consensus. Outlook: Net Cinryze sales are expected to be $235 to $260 million. Research and development and selling, general and administrative expensesare expected to be $170 to $190 million.
7:41AM Par Pharmaceutical misses by $0.06, beats on revs (PRX) 34.39 : Reports Q4 (Dec) earnings of $0.61 per share, $0.06 worse than the Thomson Reuters consensus of $0.67; revenues fell 21.8% year/year to $227 mln vs the $210.7 mln consensus.
7:39AM OM Group beats by $0.16, beats on revs (OMG) 35.82 : Reports Q4 (Dec) earnings of $0.77 per share, $0.16 better than the Thomson Reuters consensus of $0.61; revenues rose 21.1% year/year to $293.1 mln vs the $276.2 mln consensus. "As we begin 2011, we expect to continue to produce profitable growth and steadily increasing value creation for our shareholders, thanks to our truly global footprint and market-leading positions in fast-growing end markets... Assuming macroeconomic conditions remain relatively steady, we expect to see continued growth across our various end markets. In particular, within our growth platforms of portable power and electronic chemicals, we anticipate continued strong demand for battery materials, semiconductor, memory disk and printed circuit board products. Similarly, at this point in time, we expect industrial and automotive production to remain strong, which bodes well for powder metallurgy. We also believe growing demand for portable power and energy storage solutions from the defense, aerospace and medical sectors will benefit our specialized Battery Technologies businesses."
7:39AM CMS Energy reports EPS in-line, revs in-line (CMS) 19.35 : Reports Q4 (Dec) earnings of $0.21 per share, in-line with the Thomson Reuters consensus of $0.21; revenues rose 4.3% year/year to $1.68 bln vs the $1.68 bln consensus.
7:38AM Mylan Labs reports EPS in-line, misses on revs; guides FY11 EPS in-line, revs in-line (MYL) 22.46 : Reports Q4 (Dec) earnings of $0.45 per share, in-line with the Thomson Reuters consensus of $0.45; revenues rose 6.1% year/year to $1.43 bln vs the $1.46 bln consensus. Co issues in-line guidance for FY11, sees EPS of $1.90-2.10 vs. $1.99 Thomson Reuters consensus; sees FY11 revs of $6.1-6.4 bln vs. $6.1 bln Thomson Reuters consensus. Co sees FY11 gross margin profit in the range of 47%-49%. Co also reaffirms 2013 targets of $8.5 bln in revs and $2.75 per diluted share.

7:37AM On The Wires (WIRES) :
  • The Bon-Ton Stores (BONT) announced the signing of a license and design agreement with Mambo Graphics PTY for the exclusive launch of the Mambo brand in the United States. Under the agreement, Mambo will design the collection while Bon-Ton will manage the sourcing, manufacturing, distribution and marketing of the line.
  • China BAK Battery (CBAK) announced that the Company's Tianjin facility was awarded a new contract to supply lithium-ion high-power batteries to leading e-bike manufacturer, XDS Shenzhen Xidesheng Bicycle Co in China.
7:37AM Frontier Oil misses by $0.06, beats on revs (FTO) 26.60 : Reports Q4 (Dec) earnings of $0.03 per share, $0.06 worse than the Thomson Reuters consensus of $0.09; revenues rose 51.2% year/year to $1.65 bln vs the $1.52 bln consensus. "The big news is our proposed merger with Holly Corporation announced earlier this week, which we believe will create one of the strongest, most profitable and best capitalized independent refining companies in the United States. We are excited by the opportunities that lie ahead in combining these excellent companies with complex refineries in advantaged crude and product markets."
7:37AM EMCOR Group misses by $0.02, beats on revs; guides FY11 EPS below consensus, revs above consensus (EME) 30.29 : Reports Q4 (Dec) earnings of $0.59 per share, $0.02 worse than the Thomson Reuters consensus of $0.61; revenues fell 0.2% year/year to $1.36 bln vs the $1.27 bln consensus. Co issues mixed guidance for FY11, sees EPS of $1.45-1.85 vs. $2.10 Thomson Reuters consensus; sees FY11 revs of $5.3-5.5 bln vs. $5.26 bln Thomson Reuters consensus.
7:37AM Government Properties Income Trust beats by $0.06, beats on revs (GOV) 26.12 : Reports Q4 (Dec) funds from operations of $0.47 per share, $0.06 better than the Thomson Reuters consensus of $0.41; revenues rose 77.3% year/year to $36.7 mln vs the $34 mln consensus.
7:34AM Strategic Hotels & Resorts reports Q4 FFO of ($0.01) vs $0.02 Thomson Reuters consensus on revs of $184.5 mln vs $191.9 mln consensus; issued downside FY11 FFO guidance (BEE) 6.32 : Co issues FY11 FFO guidance in the range of ($0.02)-$0.07 vs $0.11 Thomson Reuters consensus.
7:32AM Target misses by $0.02, misses on revs (TGT) 50.26 : Reports Q4 (Jan) earnings of $1.38 per share, excluding a $0.07 tax benefit, $0.02 worse than the Thomson Reuters consensus of $1.40; revenues rose 2.8% year/year to $20.28 bln vs the $20.76 bln consensus, comps +2.4%. In the fourth quarter, the company repurchased ~7.6 million shares of its common stock at an average price of $54.60, for a total investment of $414 million.
7:29AM Plains Exploration misses by $0.09, beats on revs (PXP) 39.06 : Reports Q4 (Dec) earnings of $0.20 per share, excluding non-recurring items, $0.09 worse than the Thomson Reuters consensus of $0.29; revenues rose 11.0% year/year to $408.1 mln vs the $400.3 mln consensus.
7:28AM Ocwen Fincl misses by $0.07; revs in-line (OCN) 10.70 : Reports Q4 (Dec) EPS of $0.09, $0.07 worse than $0.16 Thomson Reuters consensus; revs increased 55.6% to $113.2 mln vs $113.90 Thomson Reuters consensus. Co reports it completed 19,999 loan modifications of which 20% were HAMP modifications which exceeded the upper end of guidance of 16,000 to 19,000.

7:20AM Cogent Communications beats by $0.06, beats on revs (CCOI) 13.86 : Reports Q4 (Dec) earnings of $0.06 per share, $0.06 better than the Thomson Reuters consensus of ($0.00); revenues rose 4.0% year/year to $69.5 mln vs the $68.5 mln consensus. Traffic growth of 13% from Q3 2010 to Q4 2010, traffic growth of 24% from Q4 2009 to Q4 2010 and traffic growth of 41% from 2009 to 2010. Total customer connections increased 4.1% to 25,046 as of December 31, 2010 from 24,065 as of September 30, 2010 and increased 17.3% from 21,349 as of December 31, 2009. Co currently has ~45.8 mln common shares outstanding.
7:18AM Express-1 Correction: Last night we incorrectly reported EPS of $0.15, when co actually reported Q4 EPS of $0.02 (XPO) 2.18 : Express-1 reported Q4 $0.02 vs $0.05 single analyst estimate; total revs rose 31% YoY to $41.6 mln - no rev estimate... "2010 was a banner year for XPO in which we made solid gains in both growth and profitability. We continue to believe that our integrated asset-light platform is well positioned for anything the economy can throw at us in 2011. We look forward to increased revenue and bottom line growth in 2011." Our prior comment has been removed.
7:16AM GrafTech Intl beats by $0.06, beats on revs (GTI) 22.43 : Reports Q4 (Dec) earnings of $0.32 per share, excluding items, $0.06 better than the Thomson Reuters consensus of $0.26; revenues rose 38.9% year/year to $281.2 mln vs the $247.7 mln consensus. Co expects that Q1 will be their weakest quarter of the year with EBITDA targeted to be in the range of $50-$55 mln. Negatively impacting 1Q11 EBITDA will be approximately $11 mln in intercompany profit in inventory elimination on sales of needle coke and $3 mln in related inventory step-up costs. The margin benefit of first quarter intercompany needle coke sales to our graphite electrode facilities will not be recognized until finished products are sold to third parties... For the full year 2011, co is targeting cash flow from operations to be in the range of $185-$215 mln, an improvement of approximately 40%.

7:15AM On The Wires (WIRES) :
  • Entegris (ENTG) announced a joint development agreement with IBM (IBM) to develop and test new filtration techniques for use in advanced semiconductor manufacturing.
  • Socket Mobile (SCKT) announced it has entered into a definitive agreement with AboCom Systems, to convert $500K of the Company's trade debt into common stock. The Company will issue a total of 282,485 unregistered common shares at $1.77 per share.
  • Mediabistro.com, a division of WebMediaBrands (WEBM) announced that it has acquired the assets of the Twittercism.com blog from Shea Bennett.
  • AECOM Technology Corporation (ACM) announced that it has been awarded a five-year, US$17.6-million planning and design contract for Phase I services of India's Hyderabad Metro Rail project.
  • Bruker (BRKR) announced that it has signed an agreement to acquire Michrom Bioresources. Michrom provides liquid chromatography instrumentation, accessories, and consumables for applications in the life science, chemical and applied markets.
  • Universal Travel Group (UTA) following its previous announcement on its new business expansion plan to franchise its recently obtained International Travel License from China National Tourism Association, announces it has granted its franchise to five more franchisees.
  • Atmel (ATML) announced a new family of QTouch capacitive touch controllers for implementing button, slider and wheel functionality on application-specific devices.
  • Power Integrations (POWI) announced that PI Expert Suite Version 8, the latest upgrade to the co's immensely popular power supply design software, is now available in simplified and traditional Chinese, Japanese, Korean, and Russian, as well as English.
  • Marvell (MRVL) announced that ASUS has chosen Marvell as a strategic partner to launch a new series of TD-SCDMA smartphones in China.
  • Bayer HealthCare Pharmaceuticals (BAYRY) and Onyx Pharmaceuticals (ONXX) announced the companies have begun enrolling patients in a Phase 3 randomized, double-blind, placebo-controlled trial evaluating Nexavar tablets in combination with the oral chemotherapeutic agent, capecitabine, versus placebo plus capecitabine for the treatment of patients with advanced breast cancer.
7:15AM AerCap beats by $0.06, beats on revs (AER) 14.00 : Reports Q4 (Dec) earnings of $0.53 per share, $0.06 better than the Thomson Reuters consensus of $0.47; revenues rose 38.3% year/year to $397.7 mln vs the $379.1 mln consensus. This increase resulted primarily from an increase in basic lease rents driven by the additional aircraft acquired in the Genesis Transaction and the deliveries of forward order aircraft. For similar reasons, net income excluding the impact of mark-to-market of interest rate caps and share-based compensation increased by 40%.
7:14AM First American Financial beats by $0.14, beats on revs (FAF) 15.61 : Reports Q4 (Dec) earnings of $0.44 per share, $0.14 better than the Thomson Reuters consensus of $0.30; revenues fell 0.8% year/year to $1.02 bln vs the $968 mln consensus.
7:14AM Kohl's increases share repurchase authorization by $2.6 bln to $3.5 bln (KSS) 52.02 : Co increases the Company's share repurchase authorization under its existing share repurchase program by $2.6 billion, to $3.5 billion. Co expects to recommence share repurchases in the coming months primarily in open market transactions, subject to market conditions, and expects to complete the program by the end of fiscal 2013.
7:13AM Lexington reports EPS in-line, misses on revs; guides FY11 FFO below consensus (LXP) 9.14 : Reports Q4 (Dec) funds from operations of $0.24 per share, in-line with the Thomson Reuters consensus of $0.24; revenues fell 0.1% year/year to $85.7 mln vs the $89.6 mln consensus. Co issues downside guidance for FY11, sees FFO of $0.90-0.93 vs. $0.99 Thomson Reuters consensus.
7:12AM Oxford Resource Partners reports Q4 (Dec) results, revs in-line (OXF) 26.18 : Reports Q4 (Dec) loss of $0.05 per share, may not be comparable to the Thomson Reuters consensus of $0.10; revenues rose 1.1% year/year to $89.3 mln vs the $88.8 mln consensus. "We believe our performance in 2011 will be driven by our fully contracted sales book and record volume along with cost efficiencies realized from the investments we made in 2010. We believe our cost per ton will be in-line in 2011 as compared to 2010, primarily from cost improvements in our Illinois Basin operations, offset by low single-digit cost inflation. With our expected average sales price increasing at least 5% and up to 7% from the 2010 level, we believe we will be able to achieve growth in our revenue, net income, adjusted EBITDA and distributable cash flow in 2011. We are excited about the future of the coal markets and for Oxford, and we expect to fully cover our distribution in 2011. And with our committed sales portfolio, we believe we are poised to provide growth in distributions to unitholders in subsequent years."

7:11AM Crude oil futures, both WTI and Brent, are continuing their respective rallies this morning (COMDX) :
  • April WTI crude surged to highs at $103.41 in overnight trade, but has since pulled back by close to 3 points; currently higher by $2.56 to $100.66.
  • April Brent crude oil rallied to as high as $119.79 in the overnight session, but has also pulled back, over 5 points, from those highs; currently higher by $3.24 to $114.49.
  • Supply disruptions in Libya and fears that the unrest could spread to other major producers in the region, including Saudi Arabia, continue to drive the market higher (note that inventory data for crude oil is due out at 11am ET this morning).
7:09AM Targa Resources beats by $0.04 (NGLS) 33.52 : Reports Q4 (Dec) earnings of $0.39 per share, $0.04 better than the Thomson Reuters consensus of $0.35.
7:07AM Symmetry Medical misses by $0.01, reports revs in-line; guides FY11 EPS below consensus, revs below consensus (SMA) 8.91 : Reports Q4 (Dec) earnings of $0.14 per share, $0.01 worse than the Thomson Reuters consensus of $0.15; revenues rose 25.7% year/year to $96 mln vs the $96.9 mln consensus. Co issues downside guidance for FY11, sees EPS of $0.57-0.65 vs. $0.69 Thomson Reuters consensus; sees FY11 revs of $363-383 mln vs. $384.52 mln Thomson Reuters consensus.
7:07AM Impax Labs beats by $0.01, misses on revs (IPXL) 22.22 : Reports Q4 (Dec) earnings of $0.23 per share, $0.01 better than the Thomson Reuters consensus of $0.22; revenues fell 43.7% year/year to $99.1 mln vs the $111.5 mln consensus. " We continue to progress toward filing the new drug application in the U.S. in the fourth quarter of 2011. In the generics division, we are taking action to favorably resolve the issue of supply of generic Adderall XR from Shire (SHPGY). We received some product from the 2010 quota in February and expect additional product from that quota in March; the first shipment of the 2011 quota is expected in early April... Impax therefore is pursuing every available means to acquire sufficient product to meet that greater demand, including aggressively enforcing its contractual rights through expedited litigation." Co previously disclosed its full year 2011 forecast on January 10, 2011. Co provides this further update to its full year 2010 forecast. Cash flows from operating activities, less capital expenditures (Free Cash Flow), planned to be positive. Gross margins as a percent of total revenues of ~50%. Total research and development expenses across the generic and brand divisions to ~$87 mln with generic R&D of ~$47 mln and brand R&D of ~$40 mln. Patent litigation expenses of ~$13 mln. Selling, general and administrative expenses of ~$65 mln. Updated February 2011 - capital expenditures to be ~$69 mln.
7:07AM Holly misses by $0.12, beats on revs (HOC) 55.31 : Reports Q4 (Dec) earnings of $0.27 per share, $0.12 worse than the Thomson Reuters consensus of $0.39; revenues rose 33.1% year/year to $2.21 bln vs the $2.13 bln consensus. "To date in the first quarter of 2011, steep discounts on WTI price related crudes compared to world oil prices and strong gasoline and diesel prices have raised margins at all three of our refineries. However, reduced production at our Navajo refinery over the last month due to the resultant impacts of a plant-wide power failure and bad weather will result in lower production than expected. Operations at Navajo are in the process of ramping back up to more typical levels."
7:06AM ANSYS beats by $0.06, beats on revs; guides Q1 EPS above consensus, revs above consensus; guides FY11 EPS in-line, revs in-line (ANSS) 53.32 : Reports Q4 (Dec) earnings of $0.65 per share, $0.06 better than the Thomson Reuters consensus of $0.59; revenues rose 10.8% year/year to $166.6 mln vs the $161.5 mln consensus. Co issues upside guidance for Q1, sees EPS of $0.53-0.56 vs. $0.53 Thomson Reuters consensus; sees Q1 revs of $151-157 mln vs. $150.04 mln Thomson Reuters consensus. Co issues in-line guidance for FY11, sees EPS of $2.27-2.35 vs. $2.32 Thomson Reuters consensus; sees FY11 revs of $640-660 mln vs. $646.74 mln Thomson Reuters consensus.
7:06AM IMAX reports EPS in-line, beats on revs (IMAX) 27.78 : Reports Q4 (Dec) earnings of $0.21 per share, in-line with the Thomson Reuters consensus of $0.21; revenues rose 27.7% year/year to $69.2 mln vs the $60.8 mln consensus. Based on theatres in backlog as of today, the Company is increasing its expectation for theatre network growth in 2011. The Company now expects to install between 80 and 90 new theatres (40 to 45 new joint revenue sharing systems and 40 to 45 new sales-type lease systems, excluding upgrades) this year. This implies year-over-year commercial multiplex network growth of at least 20%, as today's outlook is only based on theatres currently in backlog and does not account for any theatres that may both sign and install within 2011. The Company cautions that installations can slip from period to period, usually for reasons beyond its control.
7:05AM Patterson Companies misses by $0.01, misses on revs; guides FY11 EPS below consensus and previously stated guidance (PDCO) 32.74 : Reports Q3 (Jan) earnings of $0.47 per share, $0.01 worse than the Thomson Reuters consensus of $0.48; revenues rose 0.6% year/year to $824.7 mln vs the $833.1 mln consensus. Co issues downside guidance for FY11, sees EPS of $1.86-1.88 vs. $1.90 Thomson Reuters consensus and down from the previously-issued guidance of $1.89 to $1.99.
7:04AM Kohl's reports EPS in-line, revs in-line; guides Q1 EPS in-line, revs above consensus; guides FY12 EPS below consensus, revs in-line (KSS) 52.02 : Reports Q4 (Jan) earnings of $1.66 per share, in-line with the Thomson Reuters consensus of $1.66; revenues rose 6.3% year/year to $6.04 bln vs the $6.04 bln consensus. Co issues guidance for Q1, sees EPS of $0.68-0.73 vs. $0.72 Thomson Reuters consensus; sees Q1 revs +4-6% YoY to ~$4.196-4.277 bln vs. $4.19 bln Thomson Reuters consensus. Co issues guidance for FY12, sees EPS of $4.05-4.25 vs. $4.35 Thomson Reuters consensus; sees FY12 revs +4-6% to ~$19.13-19.49 bln vs. $19.41 bln Thomson Reuters consensus.
7:04AM Longwei Petroleum expects to benefit from the gasoline and diesel price increase enacted by China's National Development and Reform Commission on February 21; reaffirms guidance (LPH) 2.25 : Co announces that it expects to benefit from the gasoline and diesel price increase enacted by China's National Development and Reform Commission on February 21, 2011. The 4.5% increase, which translates to $53.20 per ton, is the second increase in the past two months and is based on a mechanism that allows the NDRC to adjust fuel prices when the cost of crude oil changes by more than 4 percent over a period of 22 working days. "The NDRC's decision will allow us to raise prices of our fuel products, which we anticipate will have a positive effect on our revenues and profits going forward. We also expect to experience a slight gross margin improvement, as our inventory on-hand is recorded on a weighted average basis and will be sold at higher market prices. Given the increase in demand for fuel and oil products as well as the fuel price increase, we are confident in our ability to meet our guidance of $500 million in revenues and $70 million in net income, or $0.62 EPS, for fiscal 2011."
7:02AM Universal Stainless/Alloy announces a base price increase of 5% on all stainless and low alloy grade bar products manufactured at its Bridgeville and Dunkirk facilities (USAP) 32.00 : Co announces a base price increase of 5% on all stainless and low alloy grade bar products manufactured at its Bridgeville and Dunkirk facilities. The increase will be effective for all new orders entered March 1, 2011. Current material and energy surcharges will remain in effect.
7:00AM LTX-Credence beats by $0.04, misses on revs; guides Q3 EPS, revs above consensus (LTXC) 8.82 : Reports Q2 (Jan) earnings of $0.18 per share, excluding non-recurring items, $0.04 better than the Thomson Reuters consensus of $0.14; revenues rose 9.4% year/year to $52.5 mln vs the $55.2 mln consensus. Co issues upside guidance for Q3, sees EPS of $0.17-0.21, excluding non-recurring items, vs. $0.13 Thomson Reuters consensus; sees Q3 revs of $57-61 mln vs. $56.97 mln Thomson Reuters consensus.
6:52AM Cinemark beats by $0.11, beats on revs (CNK) 18.66 : Reports Q4 (Dec) earnings of $0.33 per share, $0.11 better than the Thomson Reuters consensus of $0.22; revenues fell 2.1% year/year to $524.9 mln vs the $516.1 mln consensus.
6:50AM Foster Wheeler misses by $0.15, beats on revs (FWLT) 34.77 : Reports Q4 (Dec) earnings of $0.31 per share, excluding non-recurring items, $0.15 worse than the Thomson Reuters consensus of $0.46; revenues fell 4.3% year/year to $1.21 bln vs the $994.9 mln consensus. "As we have previously indicated, we expect Foster Wheeler's consolidated financial results in 2011 to reflect the lagging impact of the weak market conditions we experienced in 2009 and 2010, although we are clearly seeing encouraging signs of market recovery in each of our business groups. We see 2011 as a transition year that will likely reflect increased scope revenues in both the Global E&C Group and the Global Power Group as the year progresses, although the magnitude of the increase will be different in the two business groups and will depend to some extent on the timing of client decisions. In our Global E&C Group, scope revenue in 2011 is likely to be above the level of 2010. We expect the full-year 2011 EBITDA margin on scope revenue to be in the range of 13-15%, which would be down from the reported margin of 2010 due largely to competitive pressure. We were encouraged to see a sharp increase in our E&C bidding activity during the fourth quarter for study and FEED prospects, which can be a precursor to increased client spending over the next several years. In our Global Power Group, we expect scope revenue to be up sharply in 2011 versus 2010, reflecting the increased volume of boiler orders that we have won over the past 12 to 18 months. We expect the EBITDA margin on scope revenue in 2011 to be in the range of 14-16%."
6:47AM Magellan Health beats by $0.04, reports revs in-line; guides FY11 EPS in-line (MGLN) 49.14 : Reports Q4 (Dec) earnings of $0.95 per share, $0.04 better than the Thomson Reuters consensus of $0.91; revenues rose 4.2% year/year to $749.2 mln vs the $756.1 mln consensus. Co issues in-line guidance for FY11, sees EPS of $2.93-3.43 vs. $3.35 Thomson Reuters consensus, up from $2.84-3.33 due to share repurchases.
6:42AM Ritchie Bros. misses by $0.02, misses on revs (RBA) 26.43 : Reports Q4 (Dec) earnings of $0.13 per share, excluding non-recurring items, $0.02 worse than the Thomson Reuters consensus of $0.15; revenues fell 9.1% year/year to $88.3 mln vs the $92 mln consensus. "As we begin 2011 we see many signs of the used equipment market returning to a more balanced state. Equipment owners are more optimistic, OEM production is increasing to satisfy growing demand, and pricing has improved on most equipment categories... The success of our early auctions in 2011 and the flow of consignments for upcoming auctions provide clues to a return to brighter days ahead as we set about to offer compelling business solutions to enable the world's builders to easily and confidently exchange equipment."
6:40AM Susser misses by $0.04, reports revs in-line (SUSS) 15.78 : Reports Q4 (Dec) earnings of $0.06 per share, excluding non-recurring items, $0.04 worse than the Thomson Reuters consensus of $0.10; revenues rose 9.4% year/year to $1.01 bln vs the $1 bln consensus. Co reports 4Q same-store merchandise sales were up 7.3%. With regard to 2011, co sees Merchandise Same-Store Sales Growth 2.0-4.5%; New Retail Stores of 18-22; New Wholesale Dealer Sites of 15-30; Gross Capital Spending of $100-$125 mln. "As the recovery gains momentum in 2011, we expect to see additional growth in both merchandise and fuel volumes, although we do not expect to match the unusually strong fuel margins of 2010."
6:39AM Titan Intl beats by $0.11, beats on revs (TWI) 20.09 : Reports Q4 (Dec) earnings of $0.16 per share, excluding non-recurring items, $0.11 better than the Thomson Reuters consensus of $0.05; revenues rose 58.8% year/year to $232.7 mln vs the $193.9 mln consensus. The increase in sales was primarily due to a substantial increase in demand in the agricultural segment, up ~20%; and the earthmoving/construction segment, up ~32%.
6:36AM LKQ Corp reports EPS in-line, beats on revs; guides FY11 EPS in-line (LKQX) 24.95 : Reports Q4 (Dec) earnings of $0.28 per share, excluding non-recurring items, in-line with the Thomson Reuters consensus of $0.28; revenues rose 21.2% year/year to $674 mln vs the $640.9 mln consensus. Co issues in-line guidance for FY11, sees EPS of $1.31-1.39, excluding non-recurring items, vs. $1.35 Thomson Reuters consensus. "We continue to see opportunities for organic growth through increased use of alternative parts, an improving economy, additional geographic expansion and an enhanced product offering. Revenue from parts and services is anticipated to grow organically in 2011 at a rate of 6% to 8%." Net cash provided by operating activities for 2011 is projected to be ~$195 mln. The co estimates capital expenditures related to property and equipment will be between $85-95 mln.
6:33AM Sanderson Farms misses by $0.54, beats on revs (SAFM) 43.86 : Reports Q1 (Jan) loss of $0.87 per share, excluding non-recurring items, $0.54 worse than the Thomson Reuters consensus of ($0.33); revenues rose 1.8% year/year to $427.7 mln vs the $410 mln consensus. "We believe fiscal 2011 will be a challenging year for Sanderson Farms and our industry. We are already experiencing escalating grain prices, especially for corn, which are at near-record levels. The U.S. Department of Agriculture (USDA) recently reported that corn supplies are at their tightest levels in 15 years. Experience tells us that production adjustments will ultimately balance supply and demand and support market prices that will allow us, over time, to offset higher feed costs. Such adjustments will take time. Despite the challenging environment, we will continue to operate our business with a focus on those things we can control."
6:31AM Salix Pharma anticipates receipt of FDA Complete Response Letter on XIFAXAN 550 mg tablets supplemental new drug application (SLXP) 41.45 : Co announces that based on a telephone conversation with the FDA held last evening, co anticipates receiving a Complete Response Letter on or before the March 7, 2011 PDUFA goal date for the supplemental New Drug Application for XIFAXAN (rifaximin) 550 mg tablets for the proposed indication of treatment of non-constipation irritable bowel syndrome and IBS-related bloating.
6:31AM Integra beats by $0.07, reports revs in-line; guides Q1 revs below consensus; guides FY11 EPS in-line, revs in-line (IART) 49.88 : Reports Q4 (Dec) earnings of $0.80 per share, excluding non-recurring items, $0.07 better than the Thomson Reuters consensus of $0.73; revenues rose 5.8% year/year to $194.1 mln vs the $193.1 mln consensus. Co issues downside guidance for Q1, sees Q1 revs of -7 to -8% QoQ to ~$178.6-180.5 mln vs. $184.05 mln Thomson Reuters consensus. Co issues in-line guidance for FY11, sees EPS of $2.87-3.02, excluding non-recurring items, vs. $2.99 Thomson Reuters consensus; sees FY11 revs of $765-780 mln vs. $773.39 mln Thomson Reuters consensus. "The co anticipates revenues between $765-780 million, at current exchange rates. As has been the case in the past, we expect revenues in the first quarter of 2011 to be 7% to 8% lower than the fourth quarter of 2010, and earnings to be disproportionately lower, and that the fourth quarter of 2011 will be the strongest quarter of the year. The Company is guiding to GAAP earnings per diluted share of between $1.97 and $2.12 and to adjusted earnings per diluted share of between $2.87 and $3.02. In accordance with our usual practice, expectations for financial performance do not include the impact of acquisitions or other strategic corporate transactions that have not yet closed."
6:30AM Carrizo Oil & Gas announces 2010 proved reserve growth of 40%, reserve replacement of 752%, and provides operations update (CRZO) 37.09 : Co annnounces estimated 2010 production and year-end proved reserves and updates its results from operations. Proved Reserves and Production Year-end 2010 estimated proved reserves, as determined by co's third-party engineers, grew by 40% year-on-year to a record 842 Bcfe, consisting of 671 Bcf of natural gas, a 31% increase over 2009 levels and 28.5 MMbbls of oil, condensate and NGLs, a 92% increase over 2009. Co also announces proven reserves, which are biased on an average oil price of $76.05 per barrel and a natural gas price of $4.38 per million BTU. These prices were 32% higher and 13% higher than the prices used at the end of 2009 for oil and natural gas, respectively. Carrizo successfully replaced 752% of its estimated 2010 record production of 36.8 Bcfe.

6:27AM On The Wires (WIRES) :
  • Gold Resource Corporation (GORO) reported expansion of the mill's crushing plant at its El Aguila Project. The Aguila mill's crushing plant was improved and expanded with the addition of a tertiary crusher enabling not only additional capacity but smaller size feed to the ball mills.
  • Acacia Research Corporation (ACTG) announced that its subsidiary, Data Network Storage, has entered into a license agreement with International Business Machines Corporation (IBM). The license agreement resolves litigation that was pending in the Southern District of California.
  • Knapheide Manufacturing Company has selected BAF Technologies, a subsidiary of Clean Energy Fuels Corp. (CLNE), as the exclusive provider of aftermarket CNG fuel systems for light-duty Ford trucks configured with Knapheide service bodies.
  • Chart Industries (GTLS) announced that its wholly-owned subsidiary, Chart Energy & Chemicals, has been awarded a contract to provide the process design and proprietary equipment for a world scale Nitrogen Rejection facility with integrated Natural Gas Liquids recovery to be constructed in the State of Qatar. The contract amount for the process design and supply of the cold boxes, brazed aluminium heat exchangers and associated equipment exceeds $90 million.
6:27AM Linn Energy beats by $0.02 (LINE) 38.77 : Reports Q4 (Dec) earnings of $0.43 per share, ex-items, $0.02 better than the Thomson Reuters consensus of $0.41. LINN estimates that it will grow production more than 30 percent in 2011. The co plans to achieve this growth through a 2011 oil and gas capital program of $480 mln. The co expanded its hedge positions for 2011 through 2015 during the third quarter 2010. Based on current production estimates, the co is ~100 percent hedged on a natural gas and oil equivalent basis through 2013, 80 percent for 2014 and 50 percent for 2015. For 2011, the co is hedged at a weighted average oil price of $84.09 per Bbl and a weighted average natural gas price of $8.24 per Mcf.
6:26AM Chart Indust beats by $0.04, beats on revs; guides FY11 EPS in-line, revs above consensus (GTLS) 37.94 : Reports Q4 (Dec) earnings of $0.36 per share, excluding restructuring charges, $0.04 better than the Thomson Reuters consensus of $0.32; revenues rose 21.9% year/year to $158.8 mln vs the $151 mln consensus. Co issues mixed guidance for FY11, sees EPS of $1.70-1.90, excluding restructuring charges, vs. $1.78 Thomson Reuters consensus; sees FY11 revs of $710-750 mln vs. $693.00 mln Thomson Reuters consensus. Backlog at December 31, 2010 was $236.4 mln, up 28% from the December 31, 2009 level of $185.1 mln, and 11% higher than the backlog of $212.6 mln at September 30, 2010. Orders for the fourth quarter of 2010 were $182.2 mln compared with third quarter 2010 orders of $146.8 mln, an improvement of $35.4 mln or 24%.
6:25AM McCormick outlines strategy for growth at CAGNY Conference (MKC) 78.50 : When discussing the co's investment strategy for the year ahead, co talked about how acquisitions and joint ventures have played a role in growing the McCormick portfolio. The Company has made particularly notable progress in emerging markets which it expects to grow to 12% of sales by 2015 from 9 percent in 2010. "Following $54 million of cost reductions in 2010, McCormick expects to deliver at least $40 million of savings in 2011."
6:24AM Olympic Steel misses by $0.18, beats on revs (ZEUS) 28.10 : Reports Q4 (Dec) loss of $0.15 per share, $0.18 worse than the Thomson Reuters consensus of $0.03; revenues rose 55.4% year/year to $215.2 mln vs the $190.3 mln consensus. "We experienced strong momentum in material demand in the fourth quarter. Along with announced price increases in all of our product lines beginning in November of 2010 and continuing still, our year-end inventory positions present additional opportunities for market share growth and profitability into the coming year."
6:21AM Lexicon Pharma provides clinical pipeline update (LXRX) 1.80 : "We achieved significant progress in the advancement of our drug pipeline in 2010, led by positive results in clinical trials of LX4211 for type 2 diabetes... We also reported the results of a Phase 2a trial of LX2931 in rheumatoid arthritis, demonstrating a preliminary signal of efficacy and favorable safety profile that we believe supports exploration of higher doses in future studies." Key developments in 2010 include:
6:20AM ICON plc reports EPS in-line, beats on revs; guides FY11 EPS below consensus, revs in-line (ICLR) 21.96 : Reports Q4 (Dec) earnings of $0.36 per share, in-line with the Thomson Reuters consensus of $0.36; revenues rose 2.1% year/year to $232.1 mln vs the $228.7 mln consensus. Co issues mixed guidance for FY11, sees EPS of $1.10-1.25 vs. $1.49 Thomson Reuters consensus; sees FY11 revs of $945-980 mln vs. $961.64 mln Thomson Reuters consensus. "we are making significant investments to build additional capabilities, to leverage our scale more effectively, and to implement process and systems change necessary to prosper in the evolving market. We do not expect the benefit of our investments to be realised until late 2011 and into 2012."
6:20AM DISH Network beats by $0.02, reports revs in-line (DISH) 22.93 : Reports Q4 (Dec) earnings of $0.56 per share, $0.02 better than the Thomson Reuters consensus of $0.54; revenues rose 8.4% year/year to $3.21 bln vs the $3.21 bln consensus. DISH Network lost ~156,000 net subscribers during the quarter ended Dec. 31, 2010, giving the co ~14.133 million subscribers at year-end. The number of net subscribers gained for the full year ended Dec. 31, 2010, was ~33,000.
6:17AM Newmont Mining beats by $0.02, reports revs in-line (NEM) 59.11 : Reports Q4 (Dec) earnings of $1.16 per share, excluding non-recurring items, $0.02 better than the Thomson Reuters consensus of $1.14; revenues rose 1.2% year/year to $2.55 bln vs the $2.57 bln consensus. Outlook: 2011 attributable gold production is expected to be ~5.1-5.3 million ounces, with attributable copper production of 190 to 220 million pounds. The volume outlook reflects lower expected production at Batu Hijau as it moves into Phase 6 stripping, partially offset by higher production expected at Nevada and Ahafo. Costs applicable to sales are expected to be between $560 and $590 per ounce due to lower expected production at Batu Hijau, combined with higher expected costs for energy, labor, and contracted services. Costs applicable to sales are expected to be between $1.25 and $1.50 per pound of copper due to lower production at Batu Hijau. Reserves: Co increased attributable gold reserves by 1.7 mln ounces to 93.5 mln ounces in 2010. For 2011, Newmont has budgeted $360 mln (on a consolidated basis, including capitalized expenditures) for its exploration program, an increase of ~44% from 2010.
6:15AM Swift Energy misses by $0.10, misses on revs (SFY) 47.32 : Reports Q4 (Dec) earnings of $0.25 per share, $0.10 worse than the Thomson Reuters consensus of $0.35; revenues rose 1.0% year/year to $116 mln vs the $119.6 mln consensus. For 2011, co is targeting production to increase 25-30% and proved reserves to increase 15-20%, over respective 2010 levels. "Our improving operational efficiencies and contractually committed third party services and equipment give us confidence that we will continue to grow at a consistent pace during 2011. Corporate production in 2011 is expected to grow 25% - 30%, and reserves volumes are expected to grow 15% - 20%. Capital expenditures are expected to range from $430 million to $480 million, net of potential dispositions of non-strategic properties."
6:12AM Dollar Thrifty authorizes a share repurchase program providing for the repurchase of up to $100 million of its stock (DTG) 52.57 : The share repurchase program is discretionary and has no expiration date.
6:11AM Iron Mountain reports EPS in-line, revs in-line; guides FY11 EPS in-line, revs in-line (IRM) 25.98 : Reports Q4 (Dec) earnings of $0.30 per share, excluding non-recurring items, in-line with the Thomson Reuters consensus of $0.30; revenues rose 1.2% year/year to $789 mln vs the $789.8 mln consensus. Co issues in-line guidance for FY11, sees EPS of $1.21-1.30 vs. $1.24 Thomson Reuters consensus; sees FY11 revs of $3.175-3.240 bln vs. $3.23 bln Thomson Reuters consensus. The co expects capital expenditures for the year to be ~$245 mln. As of December 31, 2010, the co had repurchased an aggregate of 4.8 mln shares for a total cost of ~$111 mln. As of December 31, 2010, there was ~$239 mln remaining under the existing authorization for future share repurchases.
6:10AM Thermo Fisher to sell Athena Diagnostics and Lancaster Laboratories businesses for a total of $940 mln (TMO) 54.97 : Co announces that it has signed definitive agreements to sell its Athena Diagnostics and Lancaster Laboratories businesses for a total of $940 million in cash. The company reached an agreement to sell Athena Diagnostics to Quest Diagnostics (DGX) for $740 million. The business had ~$110 million in revenues for full year 2010, has ~300 employees and is part of the company's specialty diagnostics business within its Analytical Technologies Segment. Co also reached an agreement to sell Lancaster Laboratories to Eurofins Scientific SE for $200 million. The business had ~$115 million in revenues for full year 2010, has ~1,100 employees at its operations in the U.S. and Ireland, and is part of the company's biopharma services business within its Laboratory Products and Services Segment.
6:03AM Sears Hldg beats by $0.10, beats on revs (SHLD) 87.23 : Reports Q4 (Jan) earnings of $3.67 per share, excluding non-recurring items, $0.10 better than the Thomson Reuters consensus of $3.57; revenues fell 0.8% year/year to $13.14 bln vs the $12.97 bln consensus. For the quarter, domestic comparable store sales declined 1.2%, which comprises an increase at Kmart of 2.5% and a decline at Sears Domestic of 4.5%. arel. Over half of the total in both periods occurred in consumer electronics. In contrast, Sears' fo jewelry, and automotive categories generated comparable store sales during the period. Merchandise inventories at January 29, 2011 were $9.1 billion, as compared to $8.7 billion at January 30, 2010. Domestic inventory increased ~$270 million to $8.3 billion at January 29, 2011. The increase was primarily in the Kmart apparel, electronics, toys, footwear and sporting goods categories. Sears Canada's inventory levels increased ~$150 million to $868 million at January 29, 2011 primarily due to the change in exchange rates, lower sales and the timing of merchandise receipts.
5:52AM PetroQuest Energy misses by $0.10, misses on revs (PQ) 8.39 : Reports Q4 (Dec) earnings of $0.03 per share, $0.10 worse than the Thomson Reuters consensus of $0.13; revenues fell 19.5% year/year to $43.4 mln vs the $44.2 mln consensus. Co sees Q1 Production volumes (MMcfe/d) of 80 - 83. Co's FY11 CapEx budget of $110-120 mln

4:46AM Australia Economic Data (EWA) 25.42 : Dec Conference Board Leading Index +0.7% vs +0.2% in Nov
Nov Average Weekly Wages +3.9% vs +4.6% in Nov 09
Q4 Private Cap Ex +1.3% vs +6.9% in Q3
4:37AM Northern Trust to acquire Bank of Ireland Securities Services for ~$82 mln (NTRS) 52.40 : Co announces that it reached an agreement to acquire the fund administration, investment operations outsourcing and custody business of the Bank of Ireland Group, Bank of Ireland Securities Services. Co will pay up to EUR60 mln (~$82 mln) to acquire the business. It is anticipated that on completion of the transaction, co's combined assets under custody and administration in Ireland will increase by ~EUR70 bln (~$96 bln).
4:33AM Partner Comms announces the private issuance of additional Unsecured Non-Convertible Series C Notes (PTNR) 18.51 : Co announces that, following the public offering in Israel of unsecured non-convertible Series C Notes of the co pursuant to a shelf offering report dated April 15, 2010, as amended to date and in accordance with the shelf prospectus dated September 3, 2009, it has agreed with classified institutional investors in Israel to issue in a private placement an additional NIS443,514,739 in principal amount of Series C Notes (~$122 mln). The terms of the Additional Notes are identical to the terms of the currently outstanding Series C Notes previously issued.
3:28AM Endeavour Intl reports increase in proved and probable reserves in 2010; results in a 419% reserve replacement rate (END) 12.88 : Co announces an increase in proved and probable reserves as of December 31, 2010 resulting in a 419 percent reserve replacement rate of 2010 production, based on 2P reserves. Proved and probable reserves at year-end 2010 increased to 43.7 mln barrels of oil equivalent compared to 38.9 mmboe a year ago. Extensions, discoveries, sales and purchases added 6.3 mmboe during 2010. Production for the year was 1.5 mmboe.
2:38AM Crescent Finl: Piedmont Community Bank Holdings to invest $75 mln in co; acquires majority interst (CRFN) 2.17 : Co announces that they have entered into a definitive agreement pursuant to which Piedmont will invest $75 mln in co and therefore acquire a majority interest in the co. The definitive agreement provides that Piedmont will invest $75 mln in Crescent in exchange for CRFN common stock priced at $4 per share. As a result of the investment, Piedmont will own ~66% of co's shares on a fully diluted basis. In addition, the agreement provides for Piedmont to make a tender offer to co's existing shareholders to purchase up to 67% of currently outstanding common stock at a price of $4.75 per share. If the maximum number of shares is tendered, Piedmont will pay ~$30.6 mln for all such shares, and Piedmont would then own a total of ~89% of all outstanding common shares.
2:26AM Ensco beats by $0.20, beats on revs (ESV) 53.07 : Reports Q4 (Dec) earnings of $0.90 per share, $0.20 better than the Thomson Reuters consensus of $0.70; revenues fell 17.9% year/year to $408.5 mln vs the $400.7 mln consensus. Co expects further pressure on average reported jackup day rates in the first quarter as higher day rates from prior contracts are renewed at today's lower market rates, however, co adds that leading-edge market day rates for premium jackup rigs have begun to increase in some regions over the past several months. For full year 2011, jackup utilization is anticipated to increase modestly.
2:17AM Golden Star Resources misses by $0.07, reports revs in-line; increases mineral reserves by 24%; increases measured and indicated mineral resources by 63% (GSS) 3.92 : Reports Q4 (Dec) loss of $0.08 per share, $0.07 worse than the Thomson Reuters consensus of ($0.01); revs of $105.0 mln vs $105.7 mln Thomson Reuters consensus. For 2011, co sees total gold production (in oz) of 330,000-360,000 at a cash operating cost of $800 - $870 per oz. The exploration budget for 2011 is $30 mln and these funds will also be focused on resource definition drilling surrounding our operating areas in Ghana as well as very selective exploration and drilling at our other West African projects, and an increased level of exploration activity in Brazil. Additionally, co reports net of mining depletion, increased by 882,000 ounces or 24% by reaching a tonnage of 65.3 mln grading 2.20 g/t for contained gold of 4.62 mln ounces at year end. Measured and Indicated Mineral Resources increased 63% over 2009 to 54.9 mln tonnes grading 1.99 g/t gold. Inferred Mineral Resources increased 20% over 2009 to 16.5 mln tonnes grading 3.66 g/t gold.
2:09AM Concho Resources misses by $0.03, beats on revs (CXO) 108.20 : Reports Q4 (Dec) earnings of $0.75 per share, $0.03 worse than the Thomson Reuters consensus of $0.78; revenues rose 89.4% year/year to $323.2 mln vs the $313.7 mln consensus. During the fourth quarter and early into the first quarter, the co has continued to add to its oil derivative positions. For 2011, the co has 10.4 MMBbls of oil and 12.3 Bcf of natural gas hedged. For 2012, the co currently has 8.0 MMBbls of oil and 0.3 Bcf of natural gas hedged.
1:52AM Aqua America reports EPS in-line, misses on revs (WTR) 22.75 : Reports Q4 (Dec) earnings of $0.21 per share, in-line with the Thomson Reuters consensus of $0.21; revenues rose 6.8% year/year to $179.3 mln vs the $183.7 mln consensus.
1:25AM E*TRADE provides February month-to-date DARTS; +2% MoM; updates to its loan delinquencies (ETFC) 16.65 : Co reports its Daily Average Revenue Trades through February 22, 2011, and monthly delinquencies in its loan portfolio for the months of November and December 2010, and January 2011. DARTs through February 22, 2011 were ~184,000, a 2% increase from January. For the co's entire loan portfolio, total special mention delinquencies (30 to 89 days delinquent) declined 6% from December 31, 2010 to January 31, 2011, while total "at risk" delinquencies (30 to 179 days delinquent) declined by 4% during the same period.
1:17AM Yamana Gold increases mineral reserves by 26% and mineral resources by 12% (AUY) 12.44 : Co announces its mineral reserves and mineral resources for the year ended December 31, 2010. The co's total proven and probable mineral gold reserves increased by 4.5 mln ounces to 22.1 mln ounces, which represents a 26% increase over the previous year. Measured and indicated gold resources increased by 12% from 2009 to 14.5 mln ounces. Silver and copper proven and probable mineral reserves increased by 3% and 9%, respectively.
1:11AM Maxcom Telecom appoints new CEO (MXT) 3.70 : Co announces Salvador Alvarez has joined the Company as CEO, replacing William Nazaret who has been with the co for the past two years. Alvarez was most recently CEO of Medicus. Nazaret will remain with the co as an external advisor for a transition period.
 
Press Release Source: Marina Biotech, Inc. On Thursday February 24, 2011, 8:30 am EST
BOTHELL, WA--(Marketwire - 02/24/11) - Marina Biotech, Inc. (NASDAQ:MRNA - News), a leading RNAi-based drug discovery and development company, today announced that it has completed a 9 month toxicology study in non-human primates with its first drug candidate, CEQ508. CEQ508 is currently in a Phase 1b/2a clinical development program and is intended for the treatment of Familial Adenomatous Polyposis. During the study, 18 cynomolgus monkeys were administered daily oral doses of either CEQ508 or control article for 281 days. No test article-related adverse responses were identified in the following parameters: clinical observations, body weights and temperatures, serum chemistry, coagulation, hematology, urinalysis, cytokines and gross pathology. Additionally, monthly biopsies of colonic mucosa showed no evidence of local immune activation. CEQ508 was recently granted Orphan Drug Designation by the FDA's Office of Orphan Products Development.
"In preparation for an anticipated Phase 2 clinical trial, we initiated the enabling toxicology work early and are pleased to announce the recent completion of this program," stated Barry Polisky, Ph.D., Chief Scientific Officer at Marina Biotech, Inc. "Preliminary conclusions identify the No Observed Adverse Effect Level (NOAEL) for long-term daily oral administration of CEQ508 as 1x10(11) colony forming units (cfu)/day. This was the highest dose administered to these animals. We are encouraged by these results which provide important safety data for chronic administration of CEQ508."
About CEQ508
CEQ508 is the first drug candidate in a novel class of therapeutic agents utilizing the transkingdom RNA interference (tkRNAi) platform. CEQ508 comprises attenuated bacteria that are engineered to enter into dysplastic tissue and release a payload of short-hairpin RNA (shRNA), a mediator in the RNAi pathway. The shRNA targets the mRNA of Beta-catenin, which is known to be dysregulated in classical FAP. CEQ508 is being developed as an orally administered treatment to reduce the levels of Beta-catenin protein in the epithelial cells of the small and large intestine. Upon enrollment, patients will be placed in one of four dose-escalating cohorts. Following completion of the dose escalation phase, the trial plan calls for a stable-dose phase in which additional patients will receive the highest safe dose. CEQ508 will be administered daily in an oral suspension for 28 consecutive days. For more information please contact [email protected].
About FAP
CEQ508 is being developed for the treatment of Familial Adenomatous Polyposis (FAP), a hereditary condition that occurs in approximately 1:10,000 persons worldwide. FAP is caused by mutations in the Adenomatous Polyposis Coli (APC) gene. As a result of these mutations, epithelial cells lining the intestinal tract have increased levels of the protein β-catenin, which in turn, results in uncontrolled cell growth. Proliferation of the epithelial cells results in the formation of numerous (hundreds to thousands) non-cancerous growths (polyps) throughout the large intestine. By age 35, 95% of individuals with FAP have developed polyps and most will experience adverse effects including increased risk of bleeding and the potential for anemia. In more severe cases, obstruction of the intestines, abdominal pain, and severe bouts of diarrhea or constipation can occur. FAP patients are also at an increased risk of various cancers, the most concerning of which is a nearly 100% occurrence of colon cancer if measures are not taken to prevent the formation of polyps. For many patients, complete colectomy (surgical removal of the entire large intestine), usually performed in the late teenage years or early twenties, is the only viable option for treatment. However, surgical intervention is not curative as the risk of polyps forming in the remaining portions of the intestinal tract and in the small intestine continues after colectomy.
About Marina Biotech, Inc.
Marina Biotech is a biotechnology company, focused on the development and commercialization of RNA interference -- (RNAi) and RNA-based therapeutics. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs -- in hepatocellular carcinoma and bladder cancer. Marina Biotech has recently entered an exclusive agreement with Debiopharm Group for the development and commercialization of the bladder cancer program. Marina Biotech's goal is to improve human health through the development of RNAi and RNA-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at http://www.marinabio.com.
Forward-Looking Statements
Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Marina Biotech to obtain additional funding; (ii) the ability of Marina Biotech to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) the ability of Marina Biotech and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) the ability of Marina Biotech and/or a partner to obtain required governmental approvals; and (v) the ability of Marina Biotech and/or a partner to develop and commercialize products that can compete favorably with those of competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Marina Biotech's most recent periodic reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission. Marina Biotech assumes no obligation to update and supplement forward-looking statements because of subsequent events.
Contact:
 
close a 0,7200
pmc con cross sceso a 0,7950

l'azienda fa cacare...debiti up e farmaco ad inizio 3°fase..
l'a.t. serve ancora? se si..allora è ok
 
You must log in or register to reply here.

Users who are viewing this thread

Total: 1 (members: 0, guests: 1)
Back
Alto